European Commission approves EYLEA Injection for treatment of visual impairment due to DME
Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema.